---
title: "Ripretinib"
slug: "ripretinib"
date: "2023-09-04"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[Treatment of unresectable and metastatic GIST]]

# Ripretinib

- Unique “switch control” mechanism extends the spectrum of susceptible muts to those targeted by both type I & type II kinase inhibitors (Cancer Cell 2019;35:738)
- INVICTUS phase III RCT of ripretinib vs. placebo in 4th-line setting (Lancet Onc 2020;21:923) median PFS increased (6.3 vs. 1.0 mos); common s/e-alopecia, myalgia/arthralgia, fatigue, PPES, GI toxicities, cardiotoxicity
- INTRIGUE trial will assess ripretinib vs. sunitinib in the 2nd-line setting (ongoing)
